Article

FDA Approves Herceptin Biosimilar for Breast Cancer Treatment

The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.

The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.

Common expected adverse effects of Herzuma include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough and rash. Serious expected adverse effects of Herzuma include worsening of chemotherapy-induced neutropenia.

Like Herceptin, the labeling for Herzuma contains a Boxed Warning to alert health care professionals and patients about increased risks of cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

This article originally appeared on Specialty Pharmacy Times as "FDA Approves Herceptin Biosimilar Treatment of HER2-overexpressing Breast Cancer."

Related Videos
Image of man with grey hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a woman wearing a red tank top.
Image of Annie Bond.
Image of a man with rectangular glasses and short dark hair.
Related Content
Zejula-Jemperli Shows Promising Responses in Breast Cancer
December 20th 2024

Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset

Ariana Pelosci
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of a doctor holding a surgical instrument with a gloved hand.
December 17th 2024

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

Tim Cortese
Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of body.
December 16th 2024

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

Kristi Rosa
Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.
Illustration of a tumor in the left breast.
December 13th 2024

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

Jason Broderick
Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.